Literature DB >> 12085971

Signal transduction targets in androgen-independent prostate cancer.

J Zhou1, J Scholes, J T Hsieh.   

Abstract

Prostate cancer (PCa) first manifests as an androgen-dependent disease. Thus, androgen-deprivation therapy is a standard regimen for patients with metastatic PCa. Despite the initial success of androgen-deprivation therapy, PCa inevitably progresses from being androgen dependent (AD) to androgen independent (AI), and this marks the poor prognosis of this disease. Relapse of AIPCa becomes life threatening and accounts for the majority of mortality of PCa patients. Currently, no effective therapy is available for controlling AIPCa. Therefore, the challenge in providing a new intervention is to understand the fundamental changes that occur in AIPCa. Increasing evidence indicates that, under androgen-deprived milieu, several signal networks elicited by peptide growth factors dictate the AI phenotype of PCa. This review covers the latest studies investigating the potential involvement of autocrine growth factors in cell proliferation, survival, metastasis, and the reciprocal interaction with the androgen receptor pathway. In addition, loss of the negative feedback mechanism of the signal cascade further amplifies the effect of growth factors, and thus contributes significantly to the onset of AIPCa. The understanding of the signal target(s) in AIPCa should provide the new markers for prognosis and a new strategy for prevention and therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12085971     DOI: 10.1023/a:1015504015302

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  5 in total

1.  Androgen receptor (AR) cistrome in prostate differentiation and cancer progression.

Authors:  Fengtian Wang; Hari K Koul
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

2.  Antibody Microarray Analysis of Signaling Networks Regulated by Cxcl13 and Cxcr5 in Prostate Cancer.

Authors:  Christelle P El-Haibi; Rajesh Singh; Pranav Gupta; Praveen K Sharma; Krysta N Greenleaf; Shailesh Singh; James W Lillard
Journal:  J Proteomics Bioinform       Date:  2012

3.  Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.

Authors:  Moammir H Aziz; Nancy E Dreckschmidt; Ajit K Verma
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

4.  DAB2IP Plays Important Clinical Significance and Correlates With Immune Infiltration in Renal Cell Carcinoma.

Authors:  Haoyuan Cao; Jiandong Zhang; Wei Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

Review 5.  DAB2IP in cancer.

Authors:  Liang Liu; Cong Xu; Jer-Tsong Hsieh; Jianping Gong; Daxing Xie
Journal:  Oncotarget       Date:  2016-01-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.